Updates to Container Closure Systems Guidance for Human Drugs and Biological Products

Key changes

Introduction of a risk-based assessment framework for CCS; updated requirements for documentation of safety, suitability, and quality; recommendations for monitoring packaging integrity and material compatibility throughout the product shelf life.

PV impact

The update enhances the framework for monitoring and reporting safety issues related to drug-container interactions and packaging failures. PV operations and quality teams should review these guidelines to ensure that postmarketing safety surveillance effectively captures and reports any adverse events or quality defects linked to container closure system performance.

Exact policy details

Container Closure Systems Guidance

Contains non-binding recommendations.

Applies to: This guidance applies to CCSs used to package drugs and biological products, including combination products.

This document provides guiding principles for evaluating the quality of container closure systems (CCSs) used to package drugs and biological products, for human use. · p. 1 · High · Source

Submission of Comments

Comments must be submitted within 90 days of publication in the Federal Register.

Applies to: Applicable to all stakeholders wishing to provide feedback on the guidance.

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register. · p. 1 · High · Source

Applicable Applications

This guidance applies to applications including investigational new drug applications, new drug applications, abbreviated new drug applications, and biologics license applications.

Applies to: Applies to all human drugs and biological products, as well as combination products.

This guidance applies to applications including amendments and supplements to approved applications, for human drugs and biological products, as well as for combination products. · p. 1 · High · Source

Extracted documents

• Guidance for Industryhtmlhtml · high · 1 page
• Download the Draft Guidance Documentpdfpdf_text · high · 37 pages
• Search for FDA Guidance Documentshtmlhtml · high · 1 page
• Advisory Committee Guidance Documentshtmlhtml · high · 1 page